Drug Profile
OLX 514
Latest Information Update: 08 May 1998
Price :
$50
*
At a glance
- Originator Antigenics
- Class Antineoplastics; Piperazines
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Systemic inflammatory response syndrome
Most Recent Events
- 08 May 1998 Discontinued-Preclinical for Systemic inflammatory response syndrome in USA (Unknown route)
- 03 Sep 1996 Preclinical development for Systemic inflammatory response syndrome in USA (Unknown route)
- 29 Aug 1996 New profile